Treatment of metastatic malignant melanoma patients harboring BRAF(V600E) has improved drastically after the discovery of the BRAF inhibitor, vemurafenib. However, drug resistance is a recurring problem, and for patients harboring BRAF wild-type, prognoses are still very bad. Better markers for targeted therapy are therefore urgently needed.
With the use of the PamGene technology, the researchers established the individual kinase activity profiles in 26 tumor samples obtained from patients with metastatic malignant melanoma. In addition, they studied the overall exvivo inhibitory effects of vemurafenib and sunitinib on kinase activity status.
The findings show that this kind of assays give valuable information about overall tumor kinase activity. Furthermore, exposure to kinase inhibiting drugs on the chip may provide a useful tool to study mechanisms of resistance, as well as to identify predictive markers.
Read the full article Differential Inhibition of Ex-Vivo Tumor Kinase Activity by Vemurafenib in BRAF(V600E) and BRAF Wild-Type Metastatic Malignant Melanoma".